Company intelligence / Profile preview

TripleMed

Geleen, Limburg, Netherlandstriplemedical.com ↗

Ownership: Private
Development stage: Preclinical

Overview

TripleMed has developed a novel, minimally invasive device-based solution for the treatment and prevention of aortic aneurysms and type II endoleaks. After successful pilot studies and extensive preclinical testing, the company initiated pivotal clinical trials in 2020. Based on these results, they expect to obtain their first CE mark under MDR regulations in 2024[5].

Therapeutic areas: Cardiovascular
Modalities: DevicePolymer-based implant therapy
Industry: Implantable Medical Devices

Drug pipeline

1 asset

AneuFix

Pre-clinical

Indications: Aortic aneurysm, Endoleak prevention

Partnerships

Collaborated with TU Delft for early-stage polymer development[5]. No major pharma/biotech partnerships disclosed.

Beyond the preview

Go deeper on TripleMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TripleMed.

Explore the full profile